152 related articles for article (PubMed ID: 29619055)
1. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction
Aguilera MDV; Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Garcia-Migue J; Cortes S; Agusti E; Camacho C; Zhang Y; Li Y; Sabater S; Torne A; Arenas M
J Contemp Brachytherapy; 2018 Feb; 10(1):40-46. PubMed ID: 29619055
[TBL] [Abstract][Full Text] [Related]
2. Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?
Zhang Y; Ascaso C; Herreros A; Sánchez J; Sabater S; Pino MD; Li Y; Gómez G; Torné A; Biete A; Rovirosa Á
Rep Pract Oncol Radiother; 2020; 25(2):227-232. PubMed ID: 32042274
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
[TBL] [Abstract][Full Text] [Related]
4. EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma.
Zhang Y; Fornes B; Gómez G; Bentoldrà I; Carmona C; Herreros A; Sabater S; Nicolás I; Li Y; Sánchez J; Biete A; Torné A; Ascaso C; Rovirosa Á
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092163
[No Abstract] [Full Text] [Related]
5. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
[TBL] [Abstract][Full Text] [Related]
6. Vaginal dilator use more than 9 months is a main prognostic factor for reducing G2‑late vaginal complications in 3D‑vaginal‑cuff brachytherapy (interventional radiotherapy)?
Zhang Y; Noorian F; Abellana R; Rochera J; Herreros A; Antelo G; Lancellotta V; Tagliaferri L; Han Q; Torne A; Rovirosa A
Clin Transl Oncol; 2023 Jun; 25(6):1748-1755. PubMed ID: 36752959
[TBL] [Abstract][Full Text] [Related]
7. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy.
Small W; Erickson B; Kwakwa F
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1502-7. PubMed ID: 16109462
[TBL] [Abstract][Full Text] [Related]
8. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
[TBL] [Abstract][Full Text] [Related]
9. EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis.
Autorino R; Tagliaferri L; Campitelli M; Smaniotto D; Nardangeli A; Mattiucci GC; Macchia G; Gui B; Miccò M; Mascilini F; Ferrandina G; Kovacs G; Valentini V; Gambacorta MA
J Contemp Brachytherapy; 2018 Aug; 10(4):315-320. PubMed ID: 30237815
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis.
Zhang Y; Rovirosa A; Ascaso C; Herreros A; Torne A; Li Y; Biete A; Sánchez J
Brachytherapy; 2020; 19(1):60-65. PubMed ID: 31587986
[TBL] [Abstract][Full Text] [Related]
11. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
13. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
Rovirosa A; Valduvieco I; Ascaso C; Herreros A; Bautista C; Romera I; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Feb; 15(2):111-6. PubMed ID: 22855177
[TBL] [Abstract][Full Text] [Related]
14. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies.
Murakami N; Kasamatsu T; Sumi M; Yoshimura R; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Ito Y; Itami J
Radiat Oncol; 2014 Jan; 9():31. PubMed ID: 24456669
[TBL] [Abstract][Full Text] [Related]
15. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
[TBL] [Abstract][Full Text] [Related]
16. Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients.
Westerveld H; de Leeuw A; Kirchheiner K; Dankulchai P; Oosterveld B; Oinam A; Hudej R; Swamidas J; Lindegaard J; Tanderup K; Pötter R; Kirisits C;
Radiother Oncol; 2016 Sep; 120(3):420-427. PubMed ID: 27237058
[TBL] [Abstract][Full Text] [Related]
17. Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy.
Susko M; Craciunescu O; Meltsner S; Yang Y; Steffey B; Cai J; Chino J
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1099-105. PubMed ID: 26883564
[TBL] [Abstract][Full Text] [Related]
18. The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer.
Lee YC; Rash DL; Stern RL; Mayadev JS
Brachytherapy; 2013; 12(6):555-9. PubMed ID: 23880417
[TBL] [Abstract][Full Text] [Related]
19. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma.
Rovirosa Á; Herreros A; Camacho C; Ascaso C; Sánchez J; Cortés S; Sabater S; Solà J; Torné A; Arenas M
Brachytherapy; 2017; 16(6):1169-1174. PubMed ID: 28801116
[TBL] [Abstract][Full Text] [Related]
20. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results.
Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Holub K; Camarasa A; Sabater S; Oses G; García-Miguel J; Rivera Y; Arenas M
Brachytherapy; 2017; 16(1):147-152. PubMed ID: 28029590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
